Skill Checkup: A 68-Year-Old Woman With Low-Grade Fever, Headache, Body Aches, Fatigue, Nasal Congestion, and Sore Throat

Enrico Brunetti, MD


November 07, 2022

The most relevant factor in deciding on monoclonal antibody therapy is whether it is active against the currently circulating strains of COVID-19. The WHO and NICE both advise that the choice of a neutralizing monoclonal antibody may depend on emerging data on effectiveness of different antibodies against different SARS-CoV-2 variants.

Molnupiravir therapy is initiated at home within a few hours of the video visit. The patient begins to experience improvement in symptoms within a few days and tests negative by rapid antigen test 6 days after receiving therapy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.